39 results about "Cardiac conduction" patented technology

Antibodies specific to human contactin2 (CNTN2), and imaging and / or diagnostic reagents and compositions visualizing the CCS cells, therapeutic products and compositions comprising one or more of the antibodies. Methods for delivering therapeutic agents to the CCS cells. The disclosure further provides methods for visualizing the CCS cells in vivo in real time, including in a subject undergoing a cardiothoracic surgery or other cardiac intervention.

The invention provides an electrocardio physiological signal feature extraction method for heart conduction block classification, and belongs to the technical field of electrocardio physiological signals. 12-lead electrocardiosignals and auxiliary signals of a patient are collected, a wave equation is established through a water-wave-imitating interference multi-signal fusion algorithm, and a multi-lead signal interference mode is simulated; the method comprises the following steps: extracting time domain characteristic parameters including a PR interval, a QRS wave width, a QT interval and the like from a fusion signal, and calculating frequency domain characteristic parameters including power density distribution and a heart rate variability index; nonlinear dynamic characteristic parameters including a sample entropy value, a fractal dimension and the like are extracted, the conduction block type is judged according to the PR interval length and a QRS wave falling mode, and the technical problem that a weak heart conduction block characteristic signal cannot be accurately recognized through single-lead electrocardio analysis is solved.

The invention belongs to the technical field of marking devices, and provides an intraoperative heart conduction bundle detection marking pen and a detection method.The intraoperative heart conduction bundle detection marking pen comprises a pen holder body, a control circuit is arranged in the pen holder body, and a wiring end is arranged at the tail end of the pen holder body; the detection assembly comprises a first potential detection point, a second potential detection point and a current release point, and the first potential detection point, the second potential detection point and the current release point are all arranged at the front end of the pen holder main body; the marking assembly comprises a sterile marking head and a pressing triggering mechanism, and the pressing triggering mechanism controls the sterile marking head to stretch out and draw back; a current display screen and a current adjusting button are integrated on the outer surface of the pen holder body, and the detection assembly, the current display screen and the current adjusting button are all electrically connected with the control circuit. According to the method, the electrophysiological difference between the conduction beam and the myocardial cells in the hyperpolarization state is detected in real time through the double-potential detection points, the recognition accuracy is high, the problem of misjudgment of complex malformation cases is effectively solved, and mechanical damage caused by traditional suture or electrocautery marking is avoided.

Antitachycardia pacing (ATP) therapy may be delivered to the cardiac conduction system using cardiac conduction system pacing therapy. An initial cardiac conduction system ATP pulse set including three or less cardiac conduction system ATP pulses may be delivered to the patient's cardiac conduction system. A first cardiac conduction system ATP pulse of the initial cardiac conduction system ATP pulse set may be delivered at an interval configured to provide maximal capture of the cardiac conduction system.

An implantable medical device includes a plurality of implantable electrodes for sensing and pacing a heart of a patient. The plurality of electrodes includes cardiac conduction system electrodes positionable proximate a portion of a cardiac conduction system of a patient. A computing device includes processing circuitry and is operably coupled to a plurality of implantable electrodes. A computing device monitors a precardiac ejection (HS-PEP) of a heart of a patient. A change in the HS-PEP is determined based on the monitoring. A change in HS-PEP is determined to be greater than or equal to a specified threshold. Delivery of cardiac conduction system pacing therapy to the cardiac conduction system of the patient using the cardiac conduction system electrode is initiated based on the HS-PEP being greater than or equal to a specified threshold.

A medical device system includes a sensing circuit configured to sense at least one cardiac electrical signal, a therapy delivery circuit configured to deliver conduction system pacing pulses for capturing at least a portion of the cardiac conduction system and a memory configured to store a start time and an end time of a template window. The medical device system includes processing circuitry configured to acquire from the at least one cardiac electrical signal a first post-pace waveform extending over the template window and establish a template using at least the first post-pace waveform. The processing circuitry may acquire from the at least one cardiac electrical signal a second post-pace waveform extending over the template window and determine at least one morphology match score from the template and the second post-pace waveform.

This article describes systems and methods for determining whether cardiac conduction system pacing therapy may be beneficial and / or for determining how close or far a cardiac conduction system block may be using external cardiac signals. For this purpose, one or more left-sided measures can be generated based on left-sided alternative cardiac electrical activity measured using multiple left external electrodes to produce information on electrical heterogeneity.

The present disclosure includes a lead, a lead delivery system, and a method. The lead delivery system includes a lead body, at least one left bundle branch (LBB) electrode, and an anchoring device. The lead body extends from a proximal end to a distal end, with a penetrating portion of the lead body adjacent to the distal end and configured to extend through and perforate a ventricular septum of a patient's heart to position the distal end adjacent to a left ventricular endocardium of the patient's heart. The LBB electrode is coupled to the lead body adjacent to the distal end of the lead body and is configured to pace a LBB region. The anchoring device is adjacent to the distal end of the lead body and is configured to secure the lead body to the ventricular septum, with the anchoring device configured to adapt from a delivery configuration to an anchoring configuration.

The application relates to a magnetic navigation guiding tearable sheath for heart conduction bundle pacing, which comprises a sheath body and a joint fixedly connected to the rear end of the sheath body, the sheath body comprises a front soft section and a rear fixed section, and the front soft section can be arbitrarily bent; a plurality of pairs of half-ring magnets are arranged on the outer surface of the front soft section close to the head end, two half-ring magnets in each pair of half-ring magnets are symmetrically arranged and form a ring, and a gap is left between the two half-ring magnets; three electrodes are arranged on the head end of the front soft section and are uniformly distributed in the circumferential direction, the three electrodes can be combined in any two, and three electrode pairs for intracardiac potential recording and positioning are formed; each electrode is connected with an electrode lead wire, and the rear end of the sheath body is provided with an electrode tail wire interface, and the other ends of the three electrode lead wires are fixedly arranged in the electrode tail wire interface. The application is beneficial to intracardiac potential recording and positioning, is convenient to contact with the heart cavity, stably adheres to the endocardium, and ensures that the pacing electrode is stably rotated out.

An implantable medical device includes processing circuitry, the computing apparatus configured to communicate with a plurality of implantable electrodes to sense and pace a patient's heart. The plurality of electrodes include a conduction system pacing electrode positioned in a myocardium of the patient's heart. The computing apparatus is configured to monitor local muscle impedance of the patient's heart using the cardiac conduction system electrode and adapt cardiac therapy deliverable by the implantable device based on the local muscle impedance.

A detachable leadless pacemaker system for cardiac conduction bundle pacing is disclosed. The system includes a detachable leadless pacemaker and a passive leadless pacemaker. A hook-shape side electrode is inserted into a ventricular septum for cardiac conduction bundle pacing. The detachable leadless pacemaker may be arranged in a ventricle, and the passive leadless pacemaker may be arranged in an atrium, so as to realize dual-chamber pacing both in the ventricle and in the atrium. The detachable leadless pacemaker is coupled with the passive leadless pacemaker by an anti-tension reinforced wire, which is used for pulling back the detachable leadless pacemaker to a new position.

The utility model discloses a kind of radiofrequency ablation needle assemblies and ablation systems containing multifunctional divining rod type coaxial sheath, which ablation assembly includes multipurpose double-channel divining rod type insulating coaxial sheath and ablation needle, divining rod type insulating coaxial sheath is detachably connected with handle, and position adjusting member on handle realizes self-adaptive adjustment of ablation needle working end length, divining rod type insulating coaxial sheath synchronously realizes ablation, biopsy, pericardial effusion drainage, cardiac conduction bundle position marking, myocardial drug injection, ICD implantation and cardiac ECG monitoring and other surgical auxiliary diagnosis and treatment, to ensure that integrated intramyocardial intervention diagnosis and treatment are safely and effectively completed, the ablation needle assembly containing multipurpose divining rod type sheath in the utility model breaks through the bottleneck of low efficiency, complicated operation and many complications of existing radiofrequency ablation technology, and provides an innovative solution for comprehensive interventional treatment of heart disease and various tumor diseases.

Illustrative systems, devices, and methods monitor cardiac morphology during delivery of cardiac conduction system pacing therapy to determine effective cardiac conduction system pacing therapy. If effective cardiac conduction system pacing therapy is not determined, one or both of the cardiac conduction system pacing vector and atrioventricular delay may be adjusted until the monitored cardiac morphology indicates effective cardiac conduction system pacing therapy.

The present invention relates to the use of fingolimod in the preparation of an oral and nasal inhalation preparation for treating ischemic stroke, belonging to the field of pharmaceutical technology. The use of fingolimod in the preparation of an oral and nasal inhalation preparation for treating ischemic stroke, the chemical structural formula of the fingolimod is as follows. The present invention adopts the administration method of oral and nasal inhalation, uses fingolimod to treat ischemic stroke, enhances the aggregation of the drug in the lungs, inhibits the migration of pulmonary immune cells to the brain, thereby reducing the inflammation at the stroke site in the brain parenchyma, improving the damage to the nervous system at the stroke site, and promoting the recovery of damaged nerve function. Moreover, the oral and nasal inhalation administration method avoids the side effects such as cardiac conduction block and bradycardia that may be caused when fingolimod is taken orally, and provides a new type of safe and effective administration route for patients with cerebral infarction, especially those with heart disease.

Various aspects of the present disclosure are directed toward apparatuses, systems, and methods that include an implantable lead. The lead may include a taper or tapered portion and a fixation helix both configured to embed within tissue. In addition, the apparatuses, systems, and methods may include a guide wire configured to obtain and record signals from the heart tissue and facilitate placement of the fixation helix.

The invention discloses a radiofrequency ablation needle assembly and ablation system comprising a multifunctional Bu-shaped coaxial sheath, the ablation assembly comprises a multipurpose double-channel Bu-shaped insulating coaxial sheath and an ablation needle, the Bu-shaped insulating coaxial sheath is detachably connected with a handle, and a position adjusting piece on the handle realizes self-adaptive adjustment of the length of the working end of the ablation needle. The B-shaped insulating coaxial sheath synchronously realizes auxiliary surgical diagnosis and treatment such as ablation, biopsy, pericardial effusion drainage, cardiac conduction bundle position marking, myocardial drug injection, ICD implantation and cardiac ECG monitoring, and ensures that integrated myocardial interventional diagnosis and treatment are safely and effectively completed. According to the ablation needle assembly containing the multipurpose B-shaped sheath, the bottleneck that an existing radio frequency ablation technology is low in efficiency, tedious in operation and multiple in complications is broken through, and an innovative solution is provided for comprehensive interventional therapy of heart diseases and various tumor diseases.

Antibodies specific to human contactin2 (CNTN2), and imaging and / or diagnostic reagents and compositions visualizing the CCS cells, therapeutic products and compositions comprising one or more of the antibodies. Methods for delivering therapeutic agents to the CCS cells. The disclosure further provides methods for visualizing the CCS cells in vivo in real time, including in a subject undergoing a cardiothoracic surgery or other cardiac intervention.

Systems, devices, and methods for delivering conductive nanomaterials to a target location in a patient's heart to affect the patient's heart conduction system, such as delivering conductive nanomaterials into the ventricular septum of the patient's heart to improve an impaired heart conduction pathway, such as the left bundle branch.

The application discloses a detachable leadless pacemaker system which can pace cardiac conduction bundle. The specific embodiment of the system comprises: a detachable leadless pacemaker, the detachable leadless pacemaker is provided with a first data interface; a passive leadless pacemaker, the passive leadless pacemaker is provided with a second data interface; a signal line, which is connected with the first data interface and the second data interface respectively, so as to realize power supply of the detachable leadless pacemaker for the passive leadless pacemaker and data communication between the two. The detachable leadless pacemaker can be arranged in a ventricle to realize atrioventricular dual chamber pacing with the passive leadless pacemaker arranged in an atrium. An unpackaged circuit can be arranged in the passive leadless pacemaker, which is used as an electrode carrier for sensing atrial electrical signals and implementing electrical stimulation. The detachable leadless pacemaker and the passive leadless pacemaker are connected by a tensile-resistant reinforcing line, which is used for recovery operation when the detachable leadless pacemaker is repositioned.

A computer implemented method of computing a personalized safe zone for transcatheter deployment of an aortic valve prosthesis device in a subject, comprising: identifying a location of an annulus plane of an aortic valve in at least one reference image, identifying a location of a cardiac conduction region between a perforating bundle and a branching point of the left branch bundle of a conduction system of the heart in the at least one reference image, and computing the personalized safe zone for transcatheter deployment of the aortic valve prosthesis device as a function of the location of the annulus plane and the location of the conduction region.

A pacemaker system includes a drive-sense circuit (DSC) operably coupled to a pacemaker lead. The DSC generates a pace signal including electrical impulses based on a reference signal. The DSC provides the pace signal via the pacemaker lead to an electrically responsive portion of a cardiac conductive system of a subject to facilitate cardiac operation of a cardiovascular system of the subject. The DSC senses, via the pacemaker lead, cardiac electrical activity of the cardiovascular system of the subject that is generated in response to the pace signal and electrically coupled into the pacemaker lead and generates a digital signal that is representative of the cardiac electrical activity of the cardiovascular system of the subject that is sensed via the pacemaker lead. The DSC provides digital information to one or more processing modules that includes and / or is coupled to memory and that provide the reference signal to the DSC.

To diagnose an arrhythmia of a patient.SOLUTION: A system 100 for diagnosing an arrhythmia of a patient comprises: a diagnostic catheter 10 for insertion into the heart of the patient, the diagnostic catheter 10 configured to record anatomical and electrical activity data of the patient; and a processing unit. The processing unit is configured to receive the recorded electrical activity data 120, and correlate the electrical activity data 120 with the anatomic data. The processing unit comprises an algorithm configured to analyze the electrical activity at a location correlated with the anatomic data.SELECTED DRAWING: Figure 1

Described herein are systems, methods, and apparatuses for determining capture of a cardiac conduction system by a ventricular to atrial (VfA) therapy. A VfA therapy can be delivered at a plurality of different A-V delays while the electrical activity of a patient is monitored. The electrical activity can then be utilized to determine whether the cardiac conduction system of the patient has been captured by the VfA therapy.

Antibodies which bind selectively to cardiac conduction system (CCS) cells, imaging and / or diagnostic reagents and compositions visualizing the CCS cells and therapeutic products and compositions comprising one or more of the antibodies. Methods for delivering therapeutic agents to the CCS cells. The disclosure further provides methods for visualizing the CCS cells in vivo in real time, including in a subject undergoing a cardiothoracic surgery or other cardiac intervention. Compositions and methods for isolation, purification, analyses and / or transplantation of the CCS cells, including pluripotent stem cell (hiPSC)-derived or human embryonic stem cell (hESC)-derived CCS cells.

A pacemaker system includes a drive-sense circuit (DSC) operably coupled to a pacemaker lead. The DSC generates a pace signal including electrical impulses based on a reference signal. The DSC provides the pace signal via the pacemaker lead to an electrically responsive portion of a cardiac conductive system of a subject to facilitate cardiac operation of a cardiovascular system of the subject. The DSC senses, via the pacemaker lead, cardiac electrical activity of the cardiovascular system of the subject that is generated in response to the pace signal and electrically coupled into the pacemaker lead and generates a digital signal that is representative of the cardiac electrical activity of the cardiovascular system of the subject that is sensed via the pacemaker lead. The DSC provides digital information to one or more processing modules that includes and / or is coupled to memory and that provide the reference signal to the DSC.

A lead for cardiac conduction system includes a proximal end, a lead body extending from the proximal end, and a distal end extending from the lead body. The lead body includes a non-conductive spacer. The distal end includes a helix electrode distal to the spacer. The lead further includes a ring electrode proximal to the spacer and surrounding a portion of the lead body. The helix electrode includes a core disposed within a helical space of the helix electrode. Another lead for cardiac conduction system includes a proximal end, a lead body extending from the proximal end, and a distal end extending from the lead body. The distal end includes a first helix electrode extending from the lead body and a second helix electrode extending from the lead body. A tip of the first helix electrode is distal to a tip of the second helix electrode.

Systems and methods for detecting obstructions in a patient's cardiac conduction system using heart sound information are disclosed. An exemplary medical device system includes a data receiver circuit to receive heart sound information sensed from a patient, and a controller circuit to generate heart sound metrics or characteristics from received heart sound signals. The heart sound metric may include a metric indicative of the presence or absence of split S1 sound. The controller circuit may detect a Beam Branch Block (BBB) based at least in part on the heart sound metric, including to distinguish between a left Beam Branch Block (LBBB) and a right Beam Branch Block (RBBB). The BBB indicator may be provided to the user or a process that may be performed by the medical device system to optimize cardiac pacing and restore cardiac synchronization.

The present disclosure relates to a system for assisting implantation of an implantable electrode. The system may include an implantable electrode configured to deliver pacing of the cardiac conduction system, and an external electrode configured to sense electrical activity. The system may further include a computing device operably coupled to the implantable electrode and the external electrode, and configured to monitor at least one of internal electrical activity and external electrical activity, and configured to determine cardiac conduction system capture, current impairment, and impedance based on the monitored electrical activity. The computing device may be further configured to determine, based on at least one of the cardiac conduction system capture, the current impairment, and the impedance, that the implantable electrode is proximate to the cardiac conduction system and implanted in a ventricular septum wall prior to perforation into a left ventricular cavity, and to issue a first notification.

A catheter system for implanting a lead for cardiac conduction system is provided. The catheter system includes a catheter having an orifice extending from a distal end of the catheter to a proximal end of the catheter for implanting the lead, and a probe extending through the catheter. The probe includes a conductive wire covered with an insulation layer. A distal end of the wire is exposed from the insulation layer. The distal end of the wire includes a wire electrode configured to conduct pacing prior to implanting the lead.

Adaptive cardiac conduction system pacing therapy may monitor electrical activity of a patient's heart and select a cardiac conduction system pacing therapy pacing mode based on the monitored electrical activity. For instance, one or more metrics such as P-wave-to-R-wave interval and QRS complex width may be determined based on the monitored electrical activity, and one of an inhibited pacing mode, a ventricular fusion pacing mode, an atrioventricular synchronous pacing mode, and an atrial fibrillation pacing mode may be selected based on the determined one or more metrics.